Gastrointestinal research company InnoGI Technologies announced on Tuesday that it has named Dr Hajime Endo as its new strategic commercial advisor.

In the new role, Dr Endo is to provide strategic guidance and leadership for InnoGI Technologies, using his experience to drive commercial success and accelerate the firm's SurroGUT platform, which it says accurately mimics the human GI tract, to new heights.

Dr Endo has over three decades of experience and has served as both chairman and president of Lonza Japan. He has also served at companies such as Hoechst, and Procter & Gamble. He has served as a board member at the Japanese Institute for Health Food Standards (JIHFS).

Dr Behzad Mahdavi, PhD, MBA, InnoGI Technologies CEO, said: "We are thrilled to welcome Dr. Hajime Endo to the InnoGI Technologies team as our Strategic Commercial Advisor. His profound expertise and proven track record in commercial strategy and business development will be invaluable as we continue to revolutionise the field of gastrointestinal research with disruptive technologies."